A specialized data infrastructure for Long-Acting Injectables. A curated ontology of the niche — drugs, candidates, trademarks, delivery technologies, indications — kept current from public sources, with regulatory facts linked to their official FDA and EMA labels.
It lives across FDA filings, ClinicalTrials.gov, PubMed and corporate press, and no generalist platform gives the niche a formal scope. So the work of reassembling it — source by source, name by name — falls on the analyst.
Two things kept in sync: the state of every entity in the LAI landscape, and the flow of events that changes it — each event linked back to the entities it concerns.
An explicit, versioned definition of the niche: which drugs, candidates, trademarks, companies and indications qualify as long-acting injectable. The scope is a documented editorial decision — reviewable, not a keyword match.
Technologies classified across physical and chemical release families and half-life-extension mechanisms — orthogonal axes that combine. So you can isolate, say, ester prodrugs formulated as nanocrystals.
The system captures events — trials, approvals, deals, publications — and maintains the state of each entity. Every event resolves to the players it concerns, so signals and structure stay connected.
Regulatory facts link to their official FDA and EMA documents. Every other value is captured from public sources and resolved into one consistent ontology.
Every company, marketed drug, clinical candidate, trademark, proprietary delivery technology, target and indication in the LAI field — modeled as a queryable ontology, built from public sources: FDA, EMA, ClinicalTrials.gov, PubMed, corporate.
Each asset is a molecule × delivery technology × developer. Count the landscape and segment it — by phase, technology, target or modality.
Each product is a brand × authority. Read the real regulatory profile — FDA against EMA, label by label.
An interactive view of the LAI landscape. Scope a population of assets, then read it through a lens: a table, a competitive landscape, market trends over time, a positioning map — and a side-by-side compare of two to six items, FDA against EMA.
Sourced by default. Regulatory facts link to their official FDA and EMA labels — and no value is ever invented to fill a blank.
The same substrate, read through the lens of each role.
Vectora encodes that domain work — the scope, the ontology, the delivery-technology taxonomy — into the substrate itself. In a specialized field, the analysis is only as strong as the domain knowledge behind it.
You work directly with the analyst who builds and maintains the substrate — not an account manager relaying your questions.
One substrate feeds all three surfaces — unlocked per organization, as each one opens.
Explore the landscape. Scope a population, compare molecules or products, read FDA against EMA in one view.
A periodic brief of LAI events — readouts, approvals, deals — filtered to the niche.
Briefs and reports generated on demand — each claim traceable to its source.
Vectora is opening to a first group of LAI teams as design partners. Tell us about your work and we’ll be in touch.
Request access